Kaigene, Inc. — SEC Form D Filing

Kaigene, Inc. filed an SEC Form D on October 14, 2026, reporting $54.96M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 14, 2026
Amount reported
$54.96M
Round stage
Series B+
Industry
Biotechnology
Website
https://kaigene.com/en/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffer from severe autoimmune diseases where current treatments often only manage symptoms, leaving a significant unmet medical need for therapies that address the underlying cause.

Solution

Kaigene develops next-generation antibody therapeutics and novel modalities that target and eliminate pathogenic autoantibodies and regulate immune overactivity to treat autoimmune diseases.

Verdict

Investors committed to Kaigene due to the large, known unmet need within autoimmune disease and the established precedent for significant returns from antibody-based therapies in this category, not because of a truly novel therapeutic approach that redefines standard of care. They were implicitly betting on the company's ability to navigate the complex clinical development path for biologics and capture market share from existing symptom-management treatments. Upside was inherently limited by the crowded development pipeline in autoimmune antibodies and the high capital intensity required to bring such therapies to market, constraining exit velocity and potential market dominance.

Source: SEC EDGAR Form D filing